Developing molecular surveillance of SARS-CoV-2 in the Czech Republic (2021-2022).

Publication date: Jun 04, 2025

Molecular surveillance was widely used during the COVID-19 pandemic to detect rapidly emerging variants and monitor the transmission of SARS-CoV-2 within communities. In 2021, the Czech COVID-19 Genomics Consortium (COG-CZ) was set up to coordinate a new SARS-CoV-2 molecular surveillance network. In the Czech Republic, molecular surveillance employed whole genome sequencing (WGS) and variant discrimination polymerase chain reaction (VD-PCR) on samples collected through passive, active and sentinel surveillance. All WGS data was uploaded to GISAID and the PANGO lineages used by GISAID were compared to the main variants determined by VD-PCR. To assess the effectiveness and reliability of the gathered data in adapting pandemic responses, the capabilities and turnaround times of the molecular surveillance methods are evaluated. VD-PCR results were available within 48 h of sample collection for 81. 5% of cases during the Delta/Omicron transition. WGS enabled the detection of low-frequency novel variants in infection clusters. WGS surveillance showed there was community spread of AY. 20. 1, a variant that gained novel mutations within the Czech Republic. Molecular surveillance informed the implementation of public health measures; temporal comparisons of restrictions and outcomes are described. Further areas for improvement have been identified for monitoring and managing future pandemics.

Open Access PDF

Concepts Keywords
Czech COVID-19
Pandemic Czech Republic
Pcr Czech Republic
Polymerase Genome, Viral
Humans
Molecular surveillance
Pandemics
SARS-CoV-2
SARS-CoV-2 variants
Variant discrimination PCR
Whole Genome Sequencing

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH infection
disease MESH community spread
disease IDO country
disease IDO virulence
drug DRUGBANK Coenzyme M
disease MESH Emergency
disease MESH Infectious Diseases
disease IDO algorithm
disease MESH reinfection
disease MESH breakthrough infections
disease IDO history
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO assay
disease IDO protein
disease IDO quality
drug DRUGBANK Trimebutine
disease IDO host
disease MESH morbidity
disease MESH chronic illnesses
disease MESH lung disease
drug DRUGBANK Methionine
drug DRUGBANK Nadide
disease IDO contact tracing
drug DRUGBANK Etoperidone
disease MESH influenza
disease MESH Tumor
drug DRUGBANK Trestolone
pathway REACTOME Reproduction
drug DRUGBANK Etodolac
disease IDO blood

Original Article

(Visited 1 times, 1 visits today)